Gram-positive bacteria

Acurx Pharmaceuticals to Discuss 2021 Third Quarter Financial Results on November 15, 2021 Conference Call and Provide Business Update

Retrieved on: 
Wednesday, October 27, 2021
DRSP, Medication, Gram, IIIC, Fast Track, Infection, Methicillin-resistant Staphylococcus aureus, Patient, NASDAQ, QIDP, FDA, Food, GPSS, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, VRE, Gram-positive bacteria, MRSA, Maintenance, Company, Clostridioides difficile (bacteria), CDC, Enterococcus, Clostridioides, Firmicutes, CDI, GAIN, Act, Actinobacteria, DNA, Pharmaceutical industry, Antibiotics

David P. Luci, President and Chief Executive Officer, and Robert G. Shawah, Chief Financial Officer, will host a conference call to discuss the results and provide a business update as follows:

Key Points: 
  • David P. Luci, President and Chief Executive Officer, and Robert G. Shawah, Chief Financial Officer, will host a conference call to discuss the results and provide a business update as follows:
    Ibezapolstat is a novel, orally administered antibiotic being developed as a Gram-Positive Selective Spectrum (GPSS) antibacterial.
  • It is the first of a new class of DNA polymerase IIIC inhibitors under development by Acurx to treat bacterial infections.
  • Acurx Pharmaceuticals is a clinical stage biopharmaceutical company focused on developing new antibiotics for difficult to treat infections.
  • To learn more about Acurx Pharmaceuticals and its product pipeline please visit www.acurxpharma.com .

DGAP-News: AiCuris announces expansion of its collaboration with Lysando with a focus on diabetic foot infections

Retrieved on: 
Friday, October 22, 2021
MSD, Infection, Nitric oxide, Diabetes, Biotechnology, Cell wall, HCMV, Diagnosis, Quality of life, Gram, Absence, CMV, Gram-positive bacteria, Immune system, Human, Virus, Patient, Gram-negative bacteria, Sepsis, Hepatitis B virus, Biofilm, Severe acute respiratory syndrome coronavirus 2, Degenerative disease, Osmotic pressure, HSV, Multiple organ dysfunction syndrome, Letermovir, Amputation, Company, Disease, Transplant, Veterinary medicine, CEO, Inflammation, Chemistry (relationship), German Future Prize, Bone marrow, WHO, Mortality, Hospital, Pathogenic bacteria, Prevalence, Incidence, Drug of last resort, HBV, Pharmaceutical industry, Vaccine, Fine chemical, Antibiotics, Artilysin(R) - a new class of molecules with a novel resistance-breaking mode of action and the potential to replace common antibiotics, Chronic Wounds and Diabetic Foot Infections, Lysando AG, AiCuris Anti-infective Cures AG, ARTILYSIN(R) - A NEW CLASS OF MOLECULES WITH A NOVEL RESISTANCE-BREAKING MODE OF ACTION AND THE POTENTIAL TO REPLACE COMMON ANTIBIOTICS, CHRONIC WOUNDS AND DIABETIC FOOT INFECTIONS, LYSANDO AG, AICURIS ANTI-INFECTIVE CURES AG

As part of the expanded collaboration, both companies are to develop new Artilysin(R)-based drug candidates for the treatment of Gram-negative bacterial bloodstream infections.

Key Points: 
  • As part of the expanded collaboration, both companies are to develop new Artilysin(R)-based drug candidates for the treatment of Gram-negative bacterial bloodstream infections.
  • Of note, in contrast to a systemic treatment, a topical formulation would also be beneficial in terms of antibiotic stewardship considerations.
  • In addition, the specificity of Artilysin(R)s ensures the preservation of the natural healthy human microbiome and impede recolonization of pathogens.
  • Bacterial infection is the likeliest single cause of delayed healing of chronic open wounds by secondary intention such as diabetic foot infections.

Acurx Pharmaceuticals to Participate in the A.G.P. Biotech and Specialty Pharma Conference October 13, 2021

Retrieved on: 
Wednesday, September 29, 2021
Methicillin-resistant Staphylococcus aureus, DRSP, Clostridioides difficile (bacteria), Infection, Gram-positive bacteria, Conference, NASDAQ, Private Securities Litigation Reform Act, DNA, Clostridioides, Medication, VRE, Enterococcus, Marketing, IIIC, Company, MRSA, Gram, QIDP, Pharmaceutical industry

Biotech and Specialty Pharma Conference on October 13 2021.

Key Points: 
  • Biotech and Specialty Pharma Conference on October 13 2021.
  • Investors participating in the virtual conference who are interested in meeting with members of Acurx Pharmaceuticals' management team should contact their A.G.P.
  • Acurx Pharmaceuticals is a clinical stage biopharmaceutical company focused on developing new antibiotics for difficult to treat infections.
  • In addition, the forward-looking statements included in this press release represent our views as of September 29, 2021.

Acurx Pharmaceuticals to Present at the H.C. Wainwright 23rd Annual Global Investment Conference September 13-15, 2021

Retrieved on: 
Tuesday, August 31, 2021
Company, DRSP, Gram, Clostridioides difficile (bacteria), Infection, Enterococcus, DNA, Private Securities Litigation Reform Act, Methicillin-resistant Staphylococcus aureus, Marketing, MRSA, Clostridioides, Gram-positive bacteria, IIIC, QIDP, VRE, Medication

Acurx Pharmaceuticals is a clinical stage biopharmaceutical company focused on developing new antibiotics for difficult to treat infections.

Key Points: 
  • Acurx Pharmaceuticals is a clinical stage biopharmaceutical company focused on developing new antibiotics for difficult to treat infections.
  • To learn more about Acurx Pharmaceuticals and its product pipeline, please visit www.acurxpharma.com .
  • In addition, the forward-looking statements included in this press release represent our views as of August 30, 2021.
  • However, while we may elect to update these forward- looking statements at some point in the future, we specifically disclaim any obligation to do so.

Acurx Pharmaceuticals to Present at the Emerging Growth Conference on August 18, 2021

Retrieved on: 
Thursday, August 12, 2021
Methicillin-resistant Staphylococcus aureus, Gram, DNA, IIIC, Company, Gram-positive bacteria, Infection, Investor, MRSA, Vancomycin-resistant Enterococcus, VRE, PRSP, Antibiotics

This live, interactive online event will provide current stockholders and the investment community the opportunity to interact with David P. Luci.

Key Points: 
  • This live, interactive online event will provide current stockholders and the investment community the opportunity to interact with David P. Luci.
  • As time permits, Mr. Luci may be able to respond to questions from participants.
  • Acurx Pharmaceuticals is a clinical stage biopharmaceutical company focused on developing new antibiotics for difficult to treat infections.
  • To learn more about Acurx Pharmaceuticals and its product pipeline, please visit www.acurxpharma.com .

Endo Presents New Investigational Collagenase Clostridium Histolyticum Data at the American Podiatric Medical Association Annual Scientific Meeting

Retrieved on: 
Thursday, July 29, 2021
Gram-positive bacteria, Collagenase clostridium histolyticum, Organisms, Collagenase, Branches of biology, Microbiology, Clostridium histolyticum, Clostridium, Podiatry, Microbial collagenase

The data are being presented as an e-poster at the American Podiatric Medical Association Annual Scientific Meeting, The National , in Denver, July 29August 1.

Key Points: 
  • The data are being presented as an e-poster at the American Podiatric Medical Association Annual Scientific Meeting, The National , in Denver, July 29August 1.
  • "These early-phase data provide new evidence suggesting that CCH could potentially be a nonsurgical option to treat this condition."
  • Collagenase clostridium histolyticum (CCH) is composed of 2 purified collagenases (AUX-I and AUX-II) that hydrolyze collagen under physiologic conditions, resulting in disruption of collagen containing structures.
  • Xiaflex (collagenase clostridium histolyticum) for injection, for intralesional use [package insert].

Endo Presents New Investigational Collagenase Clostridium Histolyticum Data at the American Podiatric Medical Association Annual Scientific Meeting

Retrieved on: 
Thursday, July 29, 2021
Gram-positive bacteria, Collagenase clostridium histolyticum, Organisms, Collagenase, Branches of biology, Microbiology, Clostridium histolyticum, Clostridium, Podiatry, Microbial collagenase

The data are being presented as an e-poster at the American Podiatric Medical Association Annual Scientific Meeting, The National , in Denver, July 29August 1.

Key Points: 
  • The data are being presented as an e-poster at the American Podiatric Medical Association Annual Scientific Meeting, The National , in Denver, July 29August 1.
  • "These early-phase data provide new evidence suggesting that CCH could potentially be a nonsurgical option to treat this condition."
  • Collagenase clostridium histolyticum (CCH) is composed of 2 purified collagenases (AUX-I and AUX-II) that hydrolyze collagen under physiologic conditions, resulting in disruption of collagen containing structures.
  • Xiaflex (collagenase clostridium histolyticum) for injection, for intralesional use [package insert].

Acurx Pharmaceuticals to Discuss 2021 Second Quarter Financial Results on August 17, 2021 Conference Call and Provide Business Update

Retrieved on: 
Wednesday, July 28, 2021
Health, Medical specialties, Antibiotic-resistant bacteria, Clostridiaceae, Clostridioides difficile, Gram-positive bacteria, Antibiotic, Fidaxomicin

It is the first of a novel class of DNA polymerase IIIC inhibitors under development by Acurx to treat bacterial infections.

Key Points: 
  • It is the first of a novel class of DNA polymerase IIIC inhibitors under development by Acurx to treat bacterial infections.
  • The CDC has designated C. difficile as an urgent threat highlighting the need for new antibiotics to treat CDI.
  • Acurx Pharmaceuticals is a clinical stage biopharmaceutical company focused on developing new antibiotics for difficult to treat infections.
  • To learn more about Acurx Pharmaceuticals and its product pipeline, please visit www.acurxpharma.com .

DALVANCE® (dalbavancin) Receives FDA Approval to Treat Acute Bacterial Skin and Skin Structure Infections in Pediatric Patients

Retrieved on: 
Friday, July 23, 2021
Medical specialties, Microbiology, Bacteriology, Bacterial diseases, Glycopeptide antibiotics, Gram-positive bacteria, Pathogenic bacteria, Dalbavancin, Antibiotics, Lipoglycopeptide, Staphylococcus aureus, Streptococcus pyogenes

NORTH CHICAGO, Ill., July 23, 2021 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that the U.S. Food and Drug Administration (FDA) approved DALVANCE(dalbavancin) for the treatment of acute bacterial skin and skin structure infections (ABSSSI) in pediatric patients from birth.

Key Points: 
  • NORTH CHICAGO, Ill., July 23, 2021 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that the U.S. Food and Drug Administration (FDA) approved DALVANCE(dalbavancin) for the treatment of acute bacterial skin and skin structure infections (ABSSSI) in pediatric patients from birth.
  • "This pediatric approval for DALVANCE as a single-dose provides a meaningful contribution to the treatment of children and infants with ABSSSI."
  • ABSSSI are bacterial infections of skin and associated tissues primarily caused by Gram-positive pathogens, including Staphylococcus aureus and Streptococcus pyogenes.
  • Results from the clinical trial in pediatric patients show that the safety findings of DALVANCE in pediatric patients were similar to those observed in adults.

Recce Pharmaceuticals Announces Lead Synthetic Anti-infective RECCE® 327 Demonstrates Outstanding Efficacy Against Necrotizing Fasciitis ‘Flesh-Eating’ Bacteria

Retrieved on: 
Tuesday, July 20, 2021
Medical specialties, Bacteriology, Branches of biology, Bacterial diseases, Gram-positive bacteria, Streptococcaceae, Pathogenic bacteria, Gangrene, Bloodstream infections, Streptococcus pyogenes, Streptococcus, Gas gangrene

S. pyogenes is a species of Gram-positive bacteria and can cause life-threatening infections such as scarlet fever, bacteremia (bacteria in the blood), pneumonia, necrotizing fasciitis, myonecrosis and streptococcal toxic shock syndrome.

Key Points: 
  • S. pyogenes is a species of Gram-positive bacteria and can cause life-threatening infections such as scarlet fever, bacteremia (bacteria in the blood), pneumonia, necrotizing fasciitis, myonecrosis and streptococcal toxic shock syndrome.
  • Recces anti-infective pipeline is unique and comprised of broad-spectrum synthetic polymer antibiotics RECCE 327, RECCE 435, and RECCE 529 for viral infections with unique mechanisms of action against hyper-mutation on bacteria and viruses, respectively.
  • Patented lead candidate RECCE 327 as an intravenous therapy, is being developed for treatment of serious and potentially life-threatening infections including sepsis due to Gram-positive and Gram-negative bacteria including their superbug forms.
  • Recces anti-infective pipeline seeks to exploit the unique capabilities of RECCE technologies targeting synergistic, unmet medical needs.